Literature DB >> 32563691

Trans IL-6 signaling does not appear to play a role in renal scarring after urinary tract infection.

Sudipti Gupta1, Guillermo Yepes Junquera2, Lauren Nicassio2, Brian Becknell3, Christina B Ching4.   

Abstract

INTRODUCTION: While inflammation is an important innate defense mechanism against infection, it can also lead to local tissue damage. The trans signaling pathway of interleukin (IL)-6 is a known mediator of inflammation. We hypothesized that the trans IL-6 signaling pathway is associated with the development of post febrile urinary tract infection (UTI) renal scarring.
OBJECTIVE: To compare soluble regulators of trans IL-6 signaling between patients with a history of febrile UTI who do or do not have renal scarring. STUDY
DESIGN: After IRB-approval, we collected urine samples in pediatric patients with a history of febrile (≥38 °C) UTI (urine culture >50 K uropathogen) with documented presence or absence of renal scarring on imaging. Samples were collected at a time when patients were not actively infected. Enzyme-linked immunosorbent assays were performed on samples for markers of trans IL-6 signaling: IL-6, soluble (s) IL-6 receptor (R), and soluble (s)gp130, a buffer in trans IL-6 signaling. Values were normalized to urine creatinine. Results were analyzed by t-test or Mann-Whitney U. Spearman rank correlation was used. A p-value of <0.05 was considered significant.
RESULTS: A total of 50 urines from patients with a history of febrile UTI were collected: 23 with and 27 without scarring. There was no difference between groups regarding age or gender. There was no significant difference in urine IL-6, sIL-6R, or sgp130 between those with and without scarring (Figure). While IL-6 values significantly correlated with sIL-6R and sgp130 in those without renal scarring, IL-6 did not correlate with sgp130 in those with scarring. Ratios of IL-6 to sgp130 and sIL-6R to sgp130 were not different between groups. DISCUSSION: The inflammatory response generated in response to infection is believed to be largely responsible for the development of renal scarring after UTI. IL-6 is a cytokine known to be induced during UTI with a pro-inflammatory pathway, known as trans signaling. This study investigated for differences in markers of trans IL-6 signaling between patients with a history of febrile UTI with and without renal scarring. There was no significant difference between the absolute values or ratio of these markers between groups.
CONCLUSIONS: Markers of trans IL-6 signaling are not different between individuals with a history of febrile UTI with and without renal scarring in the non-acute setting.
Copyright © 2020 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Interleukin-6; Pyelonephritis; Signal transduction; Urinary tract infection

Mesh:

Substances:

Year:  2020        PMID: 32563691      PMCID: PMC7686088          DOI: 10.1016/j.jpurol.2020.05.010

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  20 in total

1.  Renal cytokine responses in acute Escherichia coli pyelonephritis in IL-6-deficient mice.

Authors:  A Khalil; K Tullus; T Bartfai; M Bakhiet; G Jaremko; A Brauner
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats.

Authors:  A Huang; L S Palmer; D Hom; A E Anderson; L Kushner; I Franco
Journal:  J Urol       Date:  1999-10       Impact factor: 7.450

3.  Predictive model for serious bacterial infections among infants younger than 3 months of age.

Authors:  R G Bachur; M B Harper
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

4.  Soluble receptors to tumour necrosis factor and interleukin-6 in urine during acute pyelonephritis.

Authors:  K Tullus; R Escobar-Billing; O Fituri; Y Lu; A Brauner
Journal:  Acta Paediatr       Date:  1997-11       Impact factor: 2.299

5.  Inflammation drives renal scarring in experimental pyelonephritis.

Authors:  Birong Li; Babitha Haridas; Ashley R Jackson; Hanna Cortado; Nicholas Mayne; Rebecca Kohnken; Brad Bolon; Kirk M McHugh; Andrew L Schwaderer; John David Spencer; Christina B Ching; David S Hains; Sheryl S Justice; Santiago Partida-Sanchez; Brian Becknell
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-19

6.  Triggered Urine Interleukin-6 Correlates to Severity of Symptoms in Nonfebrile Lower Urinary Tract Infections.

Authors:  Fredrik Sundén; Daniel Butler; Björn Wullt
Journal:  J Urol       Date:  2017-02-01       Impact factor: 7.450

7.  Interleukin 6 response to urinary tract infection in childhood.

Authors:  M Benson; U Jodal; A Andreasson; A Karlsson; J Rydberg; C Svanborg
Journal:  Pediatr Infect Dis J       Date:  1994-07       Impact factor: 2.129

8.  Relationship between serum and urine interleukin-6 elevations and renal scarring in children with acute pyelonephritis.

Authors:  Ji-Nan Sheu; Meng-Chi Chen; Shan-Ming Chen; Sun-Long Chen; Shyh-Ying Chiou; Ko-Huang Lue
Journal:  Scand J Urol Nephrol       Date:  2009

9.  Do serum C-reactive protein and interleukin-6 predict kidney scarring after urinary tract infection?

Authors:  Luis Miguel Rodríguez; Belén Robles; José Manuel Marugán; Angeles Suárez; José María García Ruiz de Morales
Journal:  Indian J Pediatr       Date:  2013-05-11       Impact factor: 1.967

10.  Interleukin-6/Stat3 signaling has an essential role in the host antimicrobial response to urinary tract infection.

Authors:  Christina B Ching; Sudipti Gupta; Birong Li; Hanna Cortado; Nicholas Mayne; Ashley R Jackson; Kirk M McHugh; Brian Becknell
Journal:  Kidney Int       Date:  2018-02-21       Impact factor: 10.612

View more
  1 in total

1.  Novel urine biomarkers to distinguish UTI from culture-negative pyuria.

Authors:  Elaise B Hill; Joshua R Watson; Daniel M Cohen; David Kline; Andrew L Schwaderer; John D Spencer
Journal:  Pediatr Nephrol       Date:  2021-07-16       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.